COMPREHENSIVE SPINOFF INVESTMENT OPPORTUNITIES

Upcoming Spinoffs Over Next 12 Months (March 2026 - March 2027)

Analysis Date: March 2, 2026

Methodology: This comprehensive analysis utilizes the three primary spinoff tracking websites (The Zen of Investing, Inside Arbitrage, and StockSpinoffs.com), the previous spinoff report (January 29, 2026), internet searches for “upcoming spinoffs,” and backwards-looking searches for announcements 24-36 months ago, as corporate spinoffs typically take 24-36 months to complete from initial announcement to distribution.

EXECUTIVE SUMMARY: KEY CHANGES SINCE LAST REPORT (January 29, 2026)

Completed Since Last Report

Major Developments

• Aptiv → Versigent: Renamed from Cyprium to Versigent (VGNT). Distribution date April 1, 2026 — IMMINENT
• S&P Global → Mobility Global: Rebranded from S&P Mobility to Mobility Global, Inc.; confidential Form 10 filed; Investor Day, roadshow, and debt offering planned for Q2
• MiniMed IPO: Roadshow launched February 24, 2026; pricing $25-$28/share for ~$784M raise at ~$7.86B valuation
• Kraft Heinz Split: PAUSED by new CEO Steve Cahillane on Feb 11, 2026 — investing $600M in growth instead
• WBD / Netflix Deal: COLLAPSED — Paramount Skydance made superior offer at $31/share (~$110.9B); Netflix declined to match; WBD being acquired in entirety, spinoff likely canceled
• Middleby Food Processing: CEO named (Mark Salman), revenue revised up to $850M, targeting Q2 2026
• FedEx Freight: Issued $3.7B in senior notes in February; Investor Day April 8

NEW Spinoffs Added to Tracking

NEW Completed Spinoffs Added to Tracking (Since Last Report Started)

Removed / Status Changed

• Kraft Heinz: Split PAUSED indefinitely
• WBD / Discovery Global: Spinoff LIKELY CANCELED (Paramount acquiring WBD in its entirety)
• Teleflex: Confirmed as $2.03B SALE (not spinoff), closing H2 2026
• CSL Seqirus: Remains INDEFINITELY POSTPONED

Part 1: Upcoming Spinoffs Overview (Next 12 Months)

IMMEDIATE OPPORTUNITIES (Next 30 Days)

Q2 2026 SPINOFFS

Q3 2026 SPINOFFS

H2 2026 SPINOFFS

2027 SPINOFFS (Approaching 12-Month Window)

Summary: 24 major spinoffs/separations identified over the next 12 months, plus 4 approaching in early 2027. Most imminent: Versigent/Aptiv (April 1). Largest by revenue: Honeywell Aerospace ($15B+), KDP Global Coffee Co (~$16B), FedEx Freight ($8.9B), Versigent ($9.1-9.4B), KBR Mission Tech ($5.8B). Highest quality: Mobility Global (60% margins), MiniMed (10%+ growth), Octave Intelligence (31% EBIT margins), Middleby Food Processing (26%+ margins). Major removals: Kraft Heinz (paused), WBD/Netflix (collapsed — Paramount deal instead).

Part 2: Detailed Spinoff Analysis - TOP TIER OPPORTUNITIES

1. S&P GLOBAL → MOBILITY GLOBAL ⭐ TOP PICK

Executive Summary

• Company: S&P Global Inc. (SPGI) — Current Price: ~$441.88
• SpinCo: Mobility Global, Inc. (formerly S&P Mobility)
• Industry: Automotive Data & Technology
• Expected Completion: Mid-2026
• Investment Grade: A+ (TOP PICK)
• Key Thesis: Exceptional 60% EBITDA margins, iconic CARFAX brand with near-monopoly in used car data, high acquisition potential. Rebranded as Mobility Global in February 2026. Confidential Form 10 filed; public filing, Investor Day, equity roadshow, and debt offering all planned for Q2.

Transaction Overview

• Original Company: S&P Global — financial information and analytics leader (credit ratings, indices, data)
• SpinCo: Mobility Global, Inc. — automotive data and technology leader with brands including CARFAX, automotiveMastermind, Polk Automotive Solutions, Market Scan ($1.6B revenue, 8% growth)
• RemainCo: S&P Global — focus on core financial markets: ratings, indices, Platts commodities, Market Intelligence
• Rationale: Sharpen focus on financial markets while giving Mobility autonomy to grow in $30B+ automotive data market

Financial Structure

Key Developments Since Last Report

• February 3, 2026: Rebranded as Mobility Global, Inc. — SPGI stock slid 10% on the news
• Form 10: Confidentially filed with SEC; public filing expected Q2 2026
• Q2 2026 Planned Events: Investor Day, equity roadshow, public debt offering (targeting investment-grade rating)
• Leadership: Bill Eager confirmed as designated CEO

Management Team

Transaction Timeline

• April 29, 2025: Spinoff announced
• November 13, 2025: S&P Global Investor Day (details provided)
• February 3, 2026: Rebranded as Mobility Global, Inc.
• Q2 2026: Confidential Form 10 becomes public; Investor Day; equity roadshow; debt offering
• Mid-2026: Expected separation
• Record date: TBD (likely Q2 2026)

Share Distribution

• Exchange Ratio: TBD
• Tax Treatment: Tax-free for US federal tax purposes

Investment Analysis

SpinCo (Mobility Global) Strengths:

• ⭐ Exceptional 60% EBITDA margins — among highest in data businesses
• ⭐ CARFAX near-monopoly — iconic brand with decades of vehicle history data
• ⭐ Data moat — proprietary vehicle history database impossible to replicate
• 8% revenue growth despite mature automotive market
• Three complementary divisions: Used Vehicle (CARFAX), Strategy & Product Planning, New Vehicle Sales
• Serving $30B+ total addressable market
• EV transition creates NEW data opportunities (battery health, charging history)
• AI/ML analytics potential for automotive insights
• Full leadership team in place
• Targeting investment-grade credit rating (positive signal)

SpinCo Risks:

• Cyclical automotive market exposure
• Competition from dealers and OEMs building own data platforms
• Smaller scale as standalone ($1.6B revenue)
• SPGI dropped 10% on rebrand announcement — market concerned about losing the asset

SpinCo Catalysts:

• ⭐ VERY HIGH acquisition potential — CARFAX is strategic asset
• EV transition driving new data/analytics demand
• International expansion (CARFAX primarily US/Canada)
• Q2 Investor Day will be a major catalyst for price discovery

Acquisition Analysis

Potential Acquirers:

1. Cox Automotive ⭐: Owns Autotrader, Kelley Blue Book, Manheim — consolidate with CARFAX
2. Auto dealer groups (AutoNation, Lithia, CarMax): Want to own CARFAX data
3. Microsoft/Google: Automotive data for AI training
4. Private Equity (Vista, Thoma Bravo, Silver Lake): Love high-margin data businesses

Acquisition Likelihood: VERY HIGH (90%+) — CARFAX is crown jewel asset

Recommendation: ⭐⭐⭐⭐⭐ STRONG BUY

• Best-in-class spinoff opportunity
• Quality business with exceptional margins
• Action: Monitor for Q2 2026 Investor Day and public Form 10 filing. Position before record date announcement.

Sources

• S&P Global Introduces Mobility Global Brand
• S&P Global Plans Mobility Spinoff
• SPGI Shares Slide 10% After Rebrand
• Mobility Global Blog Announcement

2. MEDTRONIC → MINIMED ⭐ STRONG BUY — IPO IMMINENT

Executive Summary

• Company: Medtronic plc (MDT)
• SpinCo: MiniMed (Ticker: MMED on NASDAQ)
• Industry: Diabetes Management Devices
• Expected Completion: IPO pricing imminent (roadshow launched Feb 24, 2026)
• Investment Grade: A (STRONG BUY)
• Key Thesis: High-growth diabetes business (10%+ growth) with turnaround momentum, strong CEO, artificial pancreas technology leader. IPO roadshow live — pricing at $25-$28/share implies ~$7.86B valuation.

Transaction Overview

• Original Company: Medtronic — global medical device leader
• SpinCo: MiniMed — insulin pumps, continuous glucose monitors (CGM), automated insulin delivery systems ($2.76B revenue, 10%+ growth)
• RemainCo: Medtronic — cardiovascular, neuroscience, surgery, other medical devices
• Structure: IPO followed by split-off to shareholders (not traditional spinoff)
• Proposed Ticker: MMED (NASDAQ)

Financial Structure

Key Developments Since Last Report

• February 24, 2026: IPO roadshow launched
• IPO Terms: 28 million shares at $25-$28 per share ($700-$784M raise)
• Post-IPO Ownership: Medtronic retains ~90% of MiniMed initially
• Implied Valuation: ~$7.86B at top of range
• MiniMed intends to retain ~$350M cash on hand from IPO proceeds

Management Team

Product Pipeline

• MiniMed 780G: Leading automated insulin delivery system, integrated with Abbott’s Instinct sensor
• MiniMed Flex (8 series): Durable AID pump, FDA submission by April 2026
• MiniMed Fit: Patch pump, FDA filing targeted for fall 2026

Transaction Timeline

• 2024: Initial spinoff plans announced
• June 12, 2025: MiniMed name announced
• January 2026: IPO filed with SEC
• February 24, 2026: IPO roadshow launched ⚠️
• March 2026: IPO pricing and first trading expected
• By November 2026: Full separation from Medtronic expected

Investment Analysis

SpinCo (MiniMed) Strengths:

• ⭐ 10%+ revenue growth — well above medtech averages
• MiniMed 780G — leading automated insulin delivery system
• Abbott integration — works with FreeStyle Libre sensors
• Strong product pipeline — Flex and Fit pumps coming
• Que Dallara proven CEO leading turnaround
• Type 1 & Type 2 diabetes market growing
• IPO structure provides valuation clarity
• $7.86B valuation at top of range is reasonable for a 10%+ grower

SpinCo Risks:

• Competition from Dexcom (CGM leader), Insulet, Tandem Diabetes
• Reimbursement pressure from insurers
• Technology disruption (non-invasive glucose monitoring)
• Medtronic retains 90% initially — limited float

SpinCo Catalysts:

• MiniMed Flex/Fit FDA approvals
• International expansion
• ⭐ Acquisition target for pharma wanting devices + drugs combination
• Post-IPO secondary offerings to increase float

Acquisition Analysis

Potential Acquirers:

1. Eli Lilly / Novo Nordisk: Insulin manufacturers wanting integrated devices + drugs
2. Dexcom: CGM leader, add insulin pump capabilities
3. Abbott: Combine with FreeStyle Libre CGM for end-to-end diabetes
4. Johnson & Johnson: Re-enter diabetes market

Acquisition Likelihood: MEDIUM-HIGH (60-70%)

Recommendation: ⭐⭐⭐⭐ BUY

• High-quality growth business with strong management
• IPO pricing provides clear entry point
• Action: Consider IPO participation at $25-$28 range or buy after initial trading stabilizes

Sources

• MiniMed Announces Launch of IPO Roadshow
• Medtronic’s MiniMed Prices IPO at up to $784M
• MiniMed IPO Seeks $784M, Valuing at $7.86B

3. FEDEX → FEDEX FREIGHT ⭐ STRONG OPPORTUNITY

Executive Summary

• Company: FedEx Corporation (FDX) — Current Price: ~$387.25
• SpinCo: FedEx Freight (Ticker: FDXF on NYSE)
• Industry: Less-Than-Truckload (LTL) Freight
• Expected Completion: June 1, 2026
• Investment Grade: A- (Strong Opportunity)
• Key Thesis: Largest pure-play LTL carrier. Form 10 filed. $3.7B debt issuance completed. Investor Day April 8.

Transaction Overview

• Original Company: FedEx — global logistics and delivery conglomerate
• SpinCo: FedEx Freight — less-than-truckload (LTL) freight business
• RemainCo: FedEx — express delivery, ground, other logistics services

Financial Structure

Key Developments Since Last Report

• January 16, 2026: Form 10 filed with SEC
• February 5, 2026: FedEx Freight issued $3.7B in senior notes (proceeds transferred to FedEx Corp — typical pre-spinoff capital structure move)
• April 8, 2026: Investor Day scheduled in New York City
• Goldman Sachs serving as financial advisor; Skadden as legal counsel

Transaction Timeline

• December 2024: Initial announcement
• January 16, 2026: Form 10 filed with SEC
• February 5, 2026: $3.7B senior notes issued
• April 8, 2026: Investor Day 📅 — details on financial model, growth prospects
• June 1, 2026: Expected distribution date
• Record date: TBD (likely May 2026)

Share Distribution

• Exchange Ratio: TBD (details at Investor Day)
• Tax Treatment: Tax-free for US federal income tax purposes
• Ticker: FDXF on NYSE

Investment Analysis

SpinCo (FedEx Freight) Strengths:

• $8.9B revenue scale — North America’s largest LTL carrier
• 15.8% operating margin
• 355 terminals, 30,000 vehicles — massive footprint
• High acquisition potential in consolidating LTL market
• $3.7B debt issuance signals separation is fully on track

SpinCo Risks:

• Weak LTL industry trends — demand soft
• Tariff uncertainty (retail lawsuits filed against FedEx)
• Cyclical freight market
• $3.7B in new debt

SpinCo Catalysts:

• ⭐ Acquisition target — XPO, Old Dominion, PE firms
• LTL market recovery
• Operational improvements as standalone
• Investor Day (April 8) will be key price discovery event

Acquisition Analysis

Potential Acquirers:

1. XPO Logistics: Major LTL consolidator
2. Old Dominion Freight Line (ODFL): Leading LTL carrier
3. Private Equity (KKR, Blackstone): LTL generates steady cash flows
4. Canadian National Railway: Intermodal synergies

Acquisition Likelihood: HIGH — LTL market is consolidating

Recommendation: ⭐⭐⭐⭐ BUY

• Large scale, high acquisition potential
• Action: Watch Investor Day (April 8) for details. Position before May record date.

Sources

• FedEx Form 10 Filing Announcement
• FedEx Freight Spinoff On Track - FreightWaves
• FedEx Freight Investor Day Announcement

4. HONEYWELL → HONEYWELL AEROSPACE ⭐ STRONG OPPORTUNITY

Executive Summary

• Company: Honeywell International (HON)
• SpinCo: Honeywell Aerospace Technologies
• Industry: Aerospace
• Expected Completion: Q3 2026 (accelerated)
• Investment Grade: A (Strong Opportunity)
• Key Thesis: Part 2 of Honeywell’s 3-way split. Creates largest pure-play aerospace supplier. $37B order backlog. Full leadership team named. New segment reporting structure effective Jan 1, 2026.

Financial Highlights

Management Team

Key Developments Since Last Report

• New segment reporting structure effective January 1, 2026 (Aerospace Technologies, Building Automation, Industrial Automation, Process Automation & Technology)
• Timeline accelerated to Q3 2026 from generic H2 2026
• Form 10 filing is a prerequisite but no public filing date confirmed yet

Transaction Timeline

• February 2025: 3-way split announced
• October 2025: Solstice spinoff completed (SOLS)
• November 2025: Aerospace CEO/Chairman named
• January 2026: CFO and leadership appointments; new segment structure
• Q3 2026: Expected Aerospace distribution (ACCELERATED)
• Record date: TBD (likely Q2-Q3 2026)

Investment Analysis

SpinCo (Aerospace) Strengths:

• ⭐ $37B order backlog — exceptional visibility
• Creates largest pure-play aerospace supplier
• Strong commercial and defense exposure
• Experienced leadership team
• Tax-free to shareholders

SpinCo Risks:

• Aerospace cycle uncertainty
• Supply chain constraints
• Competition from GE Aerospace, RTX

Recommendation: ⭐⭐⭐⭐ BUY

• High-quality aerospace pure-play
• Action: Monitor for Form 10 filing and record date announcement in Q2-Q3 2026

Sources

• Honeywell Aerospace Spinoff Accelerated to Q3 2026
• Honeywell Investor Relations - About Our Spin-Offs

5. APTIV → VERSIGENT ⚠️ IMMINENT — APRIL 1, 2026

Executive Summary

• Company: Aptiv PLC (APTV) — Current Price: ~$77.69
• SpinCo: Versigent (formerly Cyprium Holdings) — Ticker: VGNT on NYSE
• Industry: Automotive Electrical Architecture
• Expected Completion: April 1, 2026 ⚠️
• Investment Grade: B+ (Solid Opportunity)
• Key Thesis: Large revenue base ($9.1-9.4B), critical EV infrastructure play, but lower margins (10.7% EBITDA). Renamed from Cyprium to Versigent with full leadership team announced.

Transaction Overview

• Original Company: Aptiv — global technology company focused on vehicle architecture and software
• SpinCo: Versigent — low voltage and high voltage electrical architectures ($9.1-9.4B projected revenue, 10.7% EBITDA margin)
• RemainCo: Aptiv — ADAS, software, connectivity (higher-margin software business)

Financial Structure

Key Developments Since Last Report

• Renamed from Cyprium Holdings to Versigent
• Ticker: VGNT on NYSE
• Full leadership team announced:
  • CEO: Joseph Liotine
  • CFO: Doug Ostermann
• Q4 2025 earnings call (Feb 2, 2026): Management provided pro forma guidance for both entities, confirming April 1 date
• Target date shifted slightly from March 31 to April 1, 2026

Transaction Timeline

• January 24, 2025: Announced
• November 14, 2025: Form 10 filed
• February 2, 2026: Pro forma guidance provided at Q4 earnings
• April 1, 2026: TARGET distribution date ⚠️
• Record date: TBD (likely late March 2026) — WATCH FOR ANNOUNCEMENT

Investment Analysis

SpinCo (Versigent) Strengths:

• $9.1-9.4B revenue scale — substantial business
• EV tailwind: Electric vehicles require MORE complex electrical architecture
• Critical high-voltage wiring expertise
• Global manufacturing footprint across 30+ countries
• Experienced CEO (Joseph Liotine)

SpinCo Risks:

• Low margins (10.7% EBITDA) — commodity-like business
• Automotive cyclicality
• Labor-intensive manufacturing
• Tariff headwinds

Recommendation: ⭐⭐⭐ HOLD/BUY on weakness

• Large scale but commodity margins
• EV exposure is positive
• Could be value play if sells off post-spinoff (expect the typical 20-30% “spinoff dip”)
• Action: Record date expected imminently. If interested, own APTV before record date.

Sources

• Aptiv to Spin Off EDS as Versigent - TradingView
• Aptiv Names Leadership for Versigent
• Aptiv Q4 Earnings Call Highlights

6. NEW: ABB → ABB ROBOTICS

Executive Summary

• Company: ABB Ltd (ABBN — Swiss listed; ABBNY US ADR)
• SpinCo: ABB Robotics (working name)
• Industry: Industrial Robotics & Automation
• Expected Completion: Q2 2026
• Investment Grade: B+ (Solid Opportunity)
• Key Thesis: Pure-play robotics company in a growing industry. $2.3B revenue, 7,000 employees. Dual listing in Switzerland and Sweden. Competing with FANUC, Yaskawa, Kuka.

Transaction Overview

• SpinCo: ABB Robotics — robotics division with manufacturing hubs in Sweden, US, and China
• RemainCo: ABB — Electrification, Motion, Process Automation divisions
• Structure: 100% spin-off via share distribution (dividend-in-kind proportional to existing holdings)
• Rationale: Limited business/technology synergies between robotics and other ABB divisions; separate governance and capital allocation will benefit both

Financial Structure

Transaction Timeline

• April 17, 2025: Spinoff announced
• 2026 AGM: Shareholder vote required
• Q2 2026: Expected listing on exchanges in Switzerland and Sweden
• Record date: TBD

Investment Analysis

SpinCo Strengths:

• Growing robotics/automation market driven by AI, reshoring, labor shortages
• Established manufacturing in key markets (Sweden, US, China)
• Pure-play robotics exposure (rare)

SpinCo Risks:

• Relatively small (~7% of ABB revenue)
• Competition from FANUC, Yaskawa, Kuka (Midea)
• Cyclical industrial demand
• Not US-listed (Swiss/Swedish exchanges)

Recommendation: ⭐⭐⭐ HOLD/WATCH

• Interesting pure-play robotics exposure
• Non-US listing limits appeal for some investors
• Action: Monitor AGM approval and listing details

Sources

• ABB Plans to Spin Off Robotics Division
• ABB to Spin Off Robotics Unit - Bloomberg

7. NEW: HEXAGON → OCTAVE INTELLIGENCE

Executive Summary

• Company: Hexagon AB (HXGBF)
• SpinCo: Octave Intelligence Limited
• Industry: Enterprise Software / Asset Lifecycle Intelligence
• Expected Completion: Late Q2 2026
• Investment Grade: B+ (Solid Opportunity)
• Key Thesis: High-margin (31% EBIT) enterprise software business. Form 10 filed Feb 12. Dual listing on Nasdaq New York and Nasdaq Stockholm. EUR 1.45B revenue.

Transaction Overview

• SpinCo: Octave Intelligence — consolidates Hexagon’s Asset Lifecycle Intelligence, Safety/Infrastructure/Geospatial divisions, plus Bricsys, ETQ, and Projectmates businesses
• RemainCo: Hexagon — manufacturing intelligence, autonomous solutions
• Structure: 100% spin-off via share distribution

Financial Structure

Transaction Timeline

• 2025: Spinoff announced; brand unveiled as “Octave”
• February 12, 2026: Form 10 filed with SEC
• Late Q2 2026: Expected listing on Nasdaq Global Select Market (New York) and Nasdaq Stockholm
• Subject to board approval, AGM approval, Form 10 effectiveness, and exchange approvals

Investment Analysis

SpinCo Strengths:

• 31% EBIT margins — high-quality software business
• Asset lifecycle intelligence is a growing market
• Dual US/Swedish listing provides broad investor access
• EUR 1.45B revenue — meaningful scale

SpinCo Risks:

• Enterprise software competition
• Foreign-listed parent (Swedish)
• Separation from Hexagon’s integrated platform

Recommendation: ⭐⭐⭐ HOLD/WATCH

• Attractive margins and US listing
• Action: Monitor Form 10 review and listing timeline

Sources

• Hexagon Announces Update on Planned Spin-Off of Octave
• Octave Unveiled: Hexagon Reveals Name for 2026 Spin-Off

Part 3: COMPLETED SPINOFFS — Extended Post-Spinoff Analysis

COMPLETED SPINOFFS SUMMARY TABLES

Table A: Overview & Ratings

All returns as of March 2, 2026 vs Day 1 price. UL adjusted for 8:9 share consolidation.

Table B: SpinCo Price Performance (Updated March 2, 2026)

* STRZ Day 1 open of $8.00 was an abnormal spike low; closing price of $11.20 used as more representative reference. ** STRZ low of $8.40 occurred on Feb 13, 2026 — 194 trading days after spinoff — a delayed, second dip rather than the typical post-spinoff pattern. *** LION was already trading pre-May 7 via SPAC structure (LGF); May 7 was the Starz separation date. Close of $8.15 used as the post-separation reference.

Table C: Parent Company Performance Post-Spinoff

* UL close on Dec 8 (first trading day post-demerger) reflects the 8-for-9 share consolidation executed alongside the MICC spinoff. The +15.7% is the true post-spinoff return. ** BDX close on Feb 9 is ex-distribution adjusted — reflects the value after distributing BD Biosciences shares to Waters.

1. SOLSTICE ADVANCED MATERIALS (SOLS) ⭐⭐⭐⭐ — UPGRADED TO BUY

Key Price Metrics (Updated March 2, 2026)

Key Developments Since Last Report

• Q4 2025 Earnings: EPS of $0.26, missed estimates of $0.38 by ~32%. Despite miss, stock rallied.
• RBC Capital: Upgraded from Sector Perform to Outperform (Jan 20, 2026)
• Mizuho: Raised price target from $65 to $80 (Feb 13, 2026), Neutral rating
• Analyst consensus: Buy, average PT ~$83.83 (range $70-$94)
• Next earnings: May 3, 2026 (EPS estimate $0.61)

Investment Thesis Update

UPGRADED from HOLD to BUY — Despite earnings miss, the stock’s strong momentum reflects growing appreciation of SOLS’s monopoly position in US uranium processing (UF6 conversion) and Solstice-brand low-GWP refrigerants. S&P 500 inclusion continues to drive institutional demand. Analyst upgrades confirm improving sentiment.

Recommendation: ⭐⭐⭐⭐ BUY

• Strong momentum, analyst upgrades
• Monopoly uranium processing position
• Consider buying dips to $70-75

Sources

• SOLS Yahoo Finance
• Mizuho Raises PT to $80

2. QNITY ELECTRONICS (Q) ⭐⭐⭐⭐ — UPGRADED TO BUY

Key Price Metrics (Updated March 2, 2026)

Key Developments Since Last Report

• Q4 Earnings Beat (Feb 26, 2026): EPS of $0.82 vs estimate of $0.64 — beat by $0.18 (28%)
• Revenue up 8.1% YoY
• FY 2026 Guidance Issued (ABOVE consensus):
  • Net sales: $4.97B - $5.17B
  • Adjusted EBITDA: $1.465B - $1.575B
  • Adjusted EPS: $3.55 - $3.95
• Management cited AI, advanced nodes, and ICS strength as key growth drivers
• Shares +3% on earnings day

Investment Thesis Update

UPGRADED from HOLD to BUY — Qnity has delivered an outstanding earnings beat and above-consensus guidance. The AI/semiconductor tailwind is clearly benefiting this business. The initial concern about the $4.2B special dividend debt load has been overcome by strong operating performance. Stock is now ABOVE its IPO opening price.

Recommendation: ⭐⭐⭐⭐ BUY

• Exceptional earnings execution
• AI/semiconductor tailwind
• Above-consensus guidance validates growth thesis
• Consider buying dips to $110-115

Sources

• Qnity Earnings Beat
• Qnity FY 2026 Guidance

3. VERSANT MEDIA GROUP (VSNT) ⚠️ SPECULATIVE

Key Price Metrics (Updated March 2, 2026)

Key Developments Since Last Report

• Stock hit a new low of $27.17 before recovering to ~$33
• Forced selling appears largely complete — stock has stabilized and bounced off lows
• First earnings report: March 3, 2026 (tomorrow!) — key catalyst
• Raymond James: Positive on sports/news focus
• Goldman Sachs: Neutral, citing secular challenges

Investment Thesis Update

The forced selling by index funds and institutional investors that cannot hold a junk-rated (BB) cable TV company appears to have run its course. The stock has bottomed and is showing modest recovery. Tomorrow’s earnings report will be the first real test of the standalone business. At 4.2x P/E and 33% EBITDA margins, this is a deep value play for contrarian investors only.

Recommendation: ⚠️ SPECULATIVE / DEEP VALUE ONLY

• First earnings (March 3) is critical catalyst
• If earnings show stability, could see further recovery
• PE take-private remains possible
• Action: Watch March 3 earnings before acting

Sources

• VSNT Stock Analysis
• Versant Earnings Preview - CNBC

4. BD / WATERS RMT — COMPLETED — NEUTRAL

Transaction Summary

BD (BDX) RemainCo — Pure-Play MedTech

$4B Capital Deployment:

Growth Drivers: Double-digit growth in biologic drug delivery, PureWick, advanced tissue regeneration, pharmacy automation; high single-digit growth in advanced patient monitoring.

Headwinds (~10% of portfolio): Alaris infusion pumps, vaccines in China, broader China market dynamics.

Note: FY2026 EPS guidance lowered from prior $14.75-$15.05 range — reduction reflects removal of the high-margin Biosciences & Diagnostics business, not operational deterioration.

Waters (WAT) Combined Entity — Life Sciences & Diagnostics Leader

Four-Division Structure Post-Combination:

2030 Long-Term Targets:

Integration Challenges

• WAT stock dropped ~12% on deal-close day — BD business arrived weaker than expected
• China demand softness, delayed U.S. export approvals to China
• Mild flu season reduced point-of-care testing volumes
• Management guided BD assets to low single-digit revenue decline in Q1 2026
• Margin pressure from higher R&D investment and Empower software subscription transition

Investment Thesis

BD is executing well as a pure-play MedTech company with strong capital allocation ($4B deployment). Waters faces near-term integration headwinds but has an attractive long-term story ($9B revenue, 32% margin targets by 2030). The key risk is whether the $345M in synergies materialize on schedule.

Recommendation: NEUTRAL — Transaction completed successfully. BD executing shareholder-friendly capital allocation. Waters facing integration challenges but long-term synergy targets are compelling. Monitor Waters quarterly for integration progress and BD for margin expansion.

Sources

• BD Completes Combination with Waters
• BD Q1 FY2026 Earnings Results
• Seeking Alpha — BDX Post Spin-Off Exam
• Waters Q4 2025 Earnings
• Waters Stock Drops on Deal-Close Day

5. MAGNUM ICE CREAM COMPANY (MICC) ⭐⭐⭐ — HOLD

Spinoff Summary

MICC (SpinCo) — World’s Largest Ice Cream Company

Analyst Ratings

Jefferies initiated with Hold (Jan 2026). Oddo BHF initiated with Outperform.

Key Developments Since Spinoff

• Margins under pressure from FX headwinds, Transition Service Agreement (TSA) costs with Unilever, and separation/restructuring charges
• Acquiring India ice cream business from Unilever in H1 2026
• Organic sales growth remains solid at 4.2%

Unilever (UL) RemainCo Performance

Note: UL price jump from ~$59 to ~$73 includes ~12.5% mechanical boost from 8-for-9 share consolidation. Adjusted for consolidation, UL shares have still appreciated meaningfully — investors approve the simplified, higher-margin portfolio focused on Beauty & Wellbeing and Personal Care.

Investment Thesis

MICC is the world’s largest pure-play ice cream company with iconic brands (Magnum, Ben & Jerry’s) and truly global reach (80 countries). Short-term margins are pressured by separation costs and TSA fees, but the 2026 guidance for 40-60bps EBITDA margin improvement suggests the path to normalization. The India acquisition adds a high-growth market. At ~$15.87 vs analyst PTs of $17.94-$18.50, there’s modest upside.

Recommendation: ⭐⭐⭐ HOLD

• Short-term margin pressure from separation costs — will normalize
• World’s largest ice cream company with unmatched global distribution
• India acquisition is a meaningful growth catalyst
• Wait for margin improvement to materialize before upgrading to BUY

Sources

• Stock Spinoffs — MICC Spinoff
• Magnum Ice Cream 2025 Full Year Results
• MarketBeat — MICC Analyst Forecast
• Seeking Alpha — MICC Hold Rating

6. MILLROSE PROPERTIES (MRP) ⭐⭐⭐⭐ — BUY

Spinoff Summary

MRP (SpinCo) — Land-Bank REIT

Analyst Ratings

2026 Outlook

• Targeting ~$1B additional invested capital deployment by mid-2026
• $10.5B total invested capital target with at least 40% outside Lennar
• Surpassed $2.2B stretch target for invested capital outside Lennar, reaching $2.4B
• Q2 2026 exit quarterly AFFO run rate of $0.78-$0.80/share
• Targeting 33% debt-to-capital ratio

Lennar (LEN) RemainCo Performance

Lennar’s asset-light model is delivering on operational efficiency (record cycle times, best-in-class leverage), but margin compression from affordability headwinds is the key concern. Q1 FY2026 earnings on March 12-13 are a key catalyst.

Investment Thesis

MRP is a unique land-bank REIT with no direct comparable. The zero termination rate, 9.2% portfolio yield, and ~8-10% dividend yield make it a compelling income play. Diversification from Lennar-only to 15 builder counterparties dramatically reduces concentration risk. The 2026 target of 40%+ invested capital outside Lennar further de-risks the model.

Recommendation: ⭐⭐⭐⭐ BUY

• Unique land-bank REIT with 8%+ dividend yield
• Zero option terminations across 142,000 homesites
• Rapid diversification: 15 counterparties, $2.4B outside Lennar
• Trading at ~89% of book value — discount to NAV
• Strong Buy consensus with 20% upside to analyst PTs

Sources

• Lennar Completes Millrose Spin-Off
• Millrose Q4 2025 Earnings
• Millrose Invested Capital Projections

7. LIONSGATE → STARZ (STRZ) + LIONSGATE STUDIOS (LION)

Spinoff Summary

Starz Entertainment (STRZ) ⚠️ SPECULATIVE

Analyst Ratings:

Key Developments:

• Stock was up ~75% from May separation through mid-2025, but has pulled back significantly
• Starz will stop disclosing subscriber counts beginning March 2026 quarter — shifting focus to OTT revenue and profitability
• 2026 guidance: low single-digit OIBDA growth, unlevered FCF of $80M-$120M

Lionsgate Studios (LION) ⭐⭐⭐ HOLD

Film/TV Slate Highlights:

• The Housemaid (Sydney Sweeney): breakout hit, $300M+ worldwide in first 6 weeks
• Upcoming tentpoles: Michael (Apr 2026), The Hunger Games: Sunrise on the Reaping (Nov 2026), Resurrection of the Christ: Part One (Mar 2027)
• Television: scripted series deliveries expected to double from FY2026 to FY2027
• Morgan Stanley projects return to >$350M OIBDA in calendar year 2026

M&A Watch: Legendary Entertainment explored acquisition of Lionsgate Studios in July-August 2025. CEO Jon Feltheimer acknowledged a strategic transaction “down the road is something that’s probably gonna happen.” Talks have cooled; companies exploring co-production deals as a first step.

Investment Thesis

The Lionsgate split created two very different companies. STRZ is a tiny-market-cap streaming play ($190M) with improving profitability (OIBDA doubled in Q4) but high leverage and the concerning decision to stop reporting subscriber counts. LION has a strong upcoming film slate (Hunger Games franchise, The Housemaid momentum) and is narrowing losses significantly, but still not profitable. Legendary M&A remains a potential catalyst.

STRZ Recommendation: ⚠️ SPECULATIVE — Tiny market cap, high leverage (2.9x), stopping subscriber disclosures is a red flag. OIBDA improvement is real but the risk profile is high.

LION Recommendation: ⭐⭐⭐ HOLD — Improving content slate and narrowing losses, but still unprofitable. The Housemaid success and Hunger Games franchise provide upside catalysts. Watch for Legendary M&A developments.

Sources

• Lions Gate Separation
• Starz Q4 2025 Earnings — Variety
• Lionsgate Q3 FY2026 Results
• Legendary/Lionsgate M&A — Variety

8. ATRIUM THERAPEUTICS (RNAM) ⚠️ — SPECULATIVE

Spinoff Summary

RNAM (SpinCo) — Preclinical Cardiac RNA Therapeutics

Pipeline

Technology Platform: Inherited Avidity’s antibody-oligonucleotide conjugate (AOC) platform, adapted for cardiac-targeted delivery of small interfering RNA (siRNA). Builds on Avidity’s skeletal muscle delivery expertise and applies it to heart tissue.

Avidity / Novartis Acquisition Status

Investment Thesis

RNAM is a high-risk, high-reward preclinical biotech. The $2.28B market cap is aggressive for a pre-revenue company with no clinical-stage assets, but reflects the potential of the cardiac-targeted AOC platform — an extension of the same technology Novartis paid $12B to acquire for neuromuscular applications. The $270M cash runway provides ~2-3 years of funding. Key catalysts are ATR-1072 IND filing (H2 2026) and ATR-1086 IND (2027).

Recommendation: ⚠️ SPECULATIVE

• Pre-revenue, preclinical — highest risk profile of any completed spinoff
• $2.28B market cap for preclinical assets is richly valued
• Well-funded ($270M) with clear catalysts (IND filings)
• Unique cardiac RNA delivery platform validated by Novartis’s $12B parent acquisition
• Not suitable for most investors — biotech specialists only

Sources

• Novartis Completes Avidity Acquisition
• Atrium Therapeutics Launch
• BioPharma Dive — Atrium Spin-Out

SPINOFF PERFORMANCE PATTERNS (Updated with 8 Data Points)

1. The “Spinoff Dip” Remains Consistent

Updated Insight: The 3-7 week dip pattern holds for major spinoffs. STRZ experienced the deepest decline (25% from Day 1 close to low) and the longest time to bottom (194 trading days) due to tiny market cap, high leverage, and structural challenges in streaming. RNAM’s modest Day 1 dip is typical for acquisition-related spinoffs where forced sellers are merger-arb funds, not index funds.

2. Quality Spinoffs Recover Strongly

Updated Insight: Quality spinoffs (investment grade, index inclusion) can nearly double from their post-spinoff lows within 4 months. MRP stands out as a different archetype — a REIT that provides steady income (~8-10% yield) rather than aggressive price recovery. STRZ shows that even speculative spinoffs can bounce meaningfully from oversold levels.

3. Parent Companies Generally Benefit

Updated Insight: 5 of 6 parents have outperformed or held steady post-spinoff. Lennar is the notable exception — margin compression from housing affordability headwinds outweighs the asset-light strategy benefits (so far). Pattern confirms that spinoffs generally unlock parent value.

COMPLETED SPINOFFS: ACQUISITIONS & EXITS

Completed Acquisition:

Acquisition Watch List:

Part 4: STATUS CHANGES & REMOVED FROM LIST

KRAFT HEINZ — SPLIT PAUSED

Original Plan: Split into Global Taste Elevation Co. ($15.4B) + North American Grocery Co. ($10.4B) in H2 2026 New Status: PAUSED as of February 11, 2026

New CEO Steve Cahillane (started Jan 1, 2026) announced the company is pausing work on the separation:

• Stated challenges are “fixable and within our control”
• Investing $600 million in marketing, sales, and R&D instead
• Pause expected to save $300M in costs in 2026
• No set end date — will revisit once company returns to profitable growth
• Sales had deteriorated since the split was announced

Impact: Removed from active spinoff list. May return if company resumes separation plans.

Sources

• Kraft Heinz Pauses Split - CNBC
• Kraft Heinz Split Paused - Bloomberg

WARNER BROS. DISCOVERY — NETFLIX DEAL COLLAPSED; PARAMOUNT ACQUIRING

Original Plan: Spinoff into Warner Bros. (Studios) + Discovery Global (Networks), followed by Netflix acquiring Warner Bros. for $72B New Status: Deal collapsed. Paramount Skydance acquiring WBD in its entirety.

Timeline of events:

• December 2025: WBD entered merger agreement with Netflix ($72B)
• February 2026: Paramount Skydance launched rival all-cash tender offer, kept raising bid
• February 24, 2026: WBD disclosed Paramount raised bid to $31/share (~$110.9B enterprise value)
• February 26, 2026: WBD board declared Paramount’s offer a “superior proposal”
• February 26, 2026: Netflix declined to raise its bid — Sarandos/Peters said deal was “no longer financially attractive”
• Expected close: September-December 2026

Impact: The Q3 2026 spinoff of Discovery Global is almost certainly canceled. WBD will be acquired in its entirety by Paramount Skydance. Removed from active spinoff list.

Sources

• Netflix Ditches WBD After Superior Offer - CNBC
• Paramount Poised to Acquire WBD - Variety

TELEFLEX — Confirmed as SALE (Not Spinoff)

Status: Definitive agreements to sell for $2.03B cash. Expected close H2 2026. No change from last report.

CSL SEQIRUS — Remains INDEFINITELY POSTPONED

Status: No change. US flu vaccine rates down 12-14%. No timeline for revisiting.

Part 5: OTHER TRACKED SPINOFFS — BRIEF UPDATES

Middleby (MIDD) → Food Processing — Q2 2026

• CEO named: Mark Salman; COO: Mark Bowie
• Revenue revised up to $850M (from $700M)
• Tim FitzGerald continues as CEO of remaining Middleby
• Also sold 51% of Residential Kitchen business to 26North for $885M valuation
• Form 10 NOT yet filed
• Grade: B+ ⭐⭐⭐

Keurig Dr Pepper (KDP) → Global Coffee Co. — Year-End 2026

• Two-part deal: First acquire JDE Peet’s for ~$18B (closing April 2026), then split into “Beverage Co.” and “Global Coffee Co.”
• Global Coffee Co: ~$16B annual sales (Keurig, Jacob’s, L’OR, Peet’s)
• Financing: ~$9B debt, $8.5B equity, ~$5B assumed bonds (4.5x leverage)
• $400M expected cost reductions for coffee business
• Tim Cofer becomes Beverage Co CEO; Global Coffee Co CEO search underway (expected by April)
• Raised $7B from private equity to support the deal
• KDP stock: ~$30.28
• Grade: B ⭐⭐⭐

Resideo (REZI) → ADI Global Distribution — H2 2026

• FY2025 sales: $7.47B; 2026 guidance: $7.80-$7.90B
• Separation still tax-free, subject to standard conditions
• Leadership: Tom Surran (Resideo), Rob Aarnes (ADI)
• Grade: B ⭐⭐⭐

KBR (KBR) → Mission Technology Solutions — Mid-to-Late 2026

• MTS: ~$5.8B revenue, ~20,000 employees
• FY2026 guidance midpoint: $8.13B revenue, $1.01B adjusted EBITDA
• Shad Evans named CFO (effective Jan 5, 2026); will become New KBR CFO post-spin
• Leading search firm engaged to find SpinCo CEO — no announcement yet
• Grade: B ⭐⭐⭐

Modine (MOD) / Gentherm (THRM) → Performance Tech RMT — Q4 2026 (NEW)

• Announced January 29, 2026
• Modine spins off Performance Technologies, immediately merges with Gentherm (Reverse Morris Trust)
• Combined entity: ~$2.6B revenue, 13% synergy-adjusted EBITDA, ~1.0x net leverage
• Post-deal: Modine shareholders ~40%, Gentherm shareholders ~60%
• Modine retains Climate Solutions as pure-play data center/HVAC company
• Subject to Gentherm shareholder approval, financing, IRS ruling, regulatory approvals
• Grade: B ⭐⭐⭐

AnaptysBio (ANAB) → Biopharma / Royalty Split — Q2 2026 (NEW)

• Separating biopharma operations from JEMPERLI royalty/milestone assets
• Two publicly traded companies
• Originally targeted year-end 2026, pulled forward to Q2 2026
• Still in audit/SEC process
• Small-cap, speculative
• Grade: B- ⭐⭐

Eaton (ETN) → Mobility Group — End Q1 2027

• Formally announced January 26, 2026 (was previously speculative)
• Separating Vehicle + eMobility segments (~11% of revenue)
• Focus: Eaton to concentrate on Electrical and Aerospace (electrification, AI, data centers, defense)
• Tax-free for US shareholders
• Subject to Form 10, board approval, regulatory requirements
• Grade: B ⭐⭐⭐

Johnson & Johnson (JNJ) → DePuy Synthes — Late 2026 / Early 2027

• Original plan: Tax-free spinoff, $9.2B revenue
• February 20, 2026: Reports emerged J&J exploring $20B+ outright sale to private equity
• Namal Nawana named worldwide president of DePuy Synthes
• Significant uncertainty: spinoff vs. PE sale
• Grade: B (pending structure clarity) ⭐⭐⭐

McKesson (MCK) → Medical-Surgical Solutions — H2 2027

• $11.4B revenue, 17% of McKesson adjusted operating profit
• Transition service agreements implemented January 1, 2026
• Expected to go public via IPO route, tax-free
• Outside 12-month window but preparation is active
• Grade: B ⭐⭐⭐

KEY TAKEAWAYS & INVESTMENT RECOMMENDATIONS

TIER 1: TOP PICKS (A+ to A)

TIER 2: SOLID OPPORTUNITIES (B+ to B)

TIER 3: CAUTION / SPECULATIVE / REMOVED

IMMEDIATE ACTION ITEMS

1. Aptiv/Versigent (April 1) ⚠️ URGENT

   • Distribution date is April 1, 2026
   • Record date expected imminently — watch for announcement
   • Must own APTV before record date to receive VGNT shares

2. MiniMed IPO ⚠️ IMMINENT

   • Roadshow launched February 24
   • IPO pricing at $25-$28/share expected within days
   • Consider IPO participation or post-IPO buy

3. FedEx Investor Day (April 8) 📅

   • Key event for FedEx Freight details
   • Record date likely to be announced at/after event

4. Versant Earnings (March 3) 📅

   • First earnings as public company — tomorrow
   • Key test for deep value thesis

5. Monitor Mobility Global

   • Q2 events: public Form 10, Investor Day, equity roadshow, debt offering
   • Position before record date announcement

PORTFOLIO CONSTRUCTION STRATEGY

Aggressive Growth Portfolio:

1. Mobility Global (60% margins, acquisition target) — S&P Global
2. MiniMed (10%+ growth, diabetes tailwind) — Medtronic
3. Honeywell Aerospace (pure-play aerospace)
4. FedEx Freight (LTL consolidation play)

Conservative Value Portfolio:

1. Mobility Global (best risk/reward)
2. Middleby Food Processing (26%+ margins)
3. Octave Intelligence (31% EBIT margins, enterprise software)
4. Solstice (SOLS) on pullbacks — uranium monopoly

Avoid:

1. Versant Media (VSNT) — cable decline (unless deep value conviction)
2. Kraft Heinz — split paused, fundamentals weak
3. WBD — being acquired by Paramount, no spinoff

CALENDAR OF KEY EVENTS

March 2026:

• March 3: Versant (VSNT) first earnings report 📅
• Mid-March: MiniMed (MMED) IPO pricing expected
• Late March: Aptiv/Versigent record date expected

April 2026:

• April 1: Aptiv → Versigent distribution ⚠️
• April 8: FedEx Investor Day 📅
• April: KDP JDE Peet’s acquisition closes

Q2 2026:

• Mobility Global: public Form 10, Investor Day, roadshow, debt offering
• ABB Robotics AGM vote and listing
• Hexagon → Octave Intelligence listing
• Middleby Food Processing separation
• AnaptysBio split
• FedEx Freight record date (expected May)

June 2026:

• June 1: FedEx Freight distribution

Q3 2026:

• Honeywell Aerospace distribution (accelerated)

H2 2026:

• MiniMed full separation from Medtronic
• KDP split into Beverage Co + Global Coffee Co
• KBR Mission Technology Solutions
• Resideo → ADI Global Distribution
• Modine/Gentherm RMT (Q4)
• Paramount/WBD deal closes (Sept-Dec)
• J&J DePuy Synthes (spinoff or PE sale)

2027:

• Eaton Mobility Group (end Q1)
• McKesson Medical-Surgical Solutions (H2)

APPENDIX: COMPLETE SPINOFF LIST (March 2026)

Completed (Now Trading):

• Honeywell → Solstice (SOLS) — Oct 2025 — $78.17 (+56% from open)
• DuPont → Qnity (Q) — Nov 2025 — $122.28 (+16% from open)
• Unilever → Magnum Ice Cream Co (MICC) — Dec 2025 — EUR 7.9B valuation, world’s largest ice cream co
• Comcast → Versant (VSNT) — Jan 2026 — $33.32 (-26% from open)
• BD → Waters RMT (WAT) — Feb 2026 — $319.44 (combined entity)
• Avidity Bio → Atrium Therapeutics (RNAM) — Feb 26, 2026 — ~$270M capitalization, pre-Novartis acquisition spin
• Lionsgate → Starz (STRZ) / Lionsgate Studios (LION) — May 2025 — Two standalone public companies
• Lennar → Millrose Properties (MRP) — Feb 2025 — $5.5B land assets, REIT

Paused / Canceled:

• Kraft Heinz → PAUSED by new CEO (Feb 11, 2026)
• WBD → CANCELED (Paramount Skydance acquiring WBD)
• Teleflex → Changed to $2.03B SALE
• CSL Seqirus → INDEFINITELY POSTPONED

Report Generated: March 2, 2026 Next Update Recommended: April 15, 2026 (after Versigent distribution, FedEx Investor Day, MiniMed IPO pricing) Methodology: The Zen of Investing, Inside Arbitrage, StockSpinoffs.com, plus backwards-looking searches for announcements 24-36 months ago Source: Spinoff Investment Analysis Skill v4.0

SOURCES

• The Zen of Investing - Upcoming Spinoffs
• Inside Arbitrage - Spinoffs
• StockSpinoffs.com
• S&P Global Investor Relations
• Medtronic Newsroom
• Honeywell Investor Relations
• FedEx Newsroom
• Aptiv Newsroom
• Hexagon Newsroom
• ABB News Center
• Middleby Investor Relations
• KBR Investor Relations
• Resideo Investor Relations
• FreightWaves
• MedTech Dive

DISCLAIMER

This report is for informational and educational purposes only. Not investment advice. Spinoff transactions are subject to change, delay, or cancellation. Always conduct your own due diligence and consult with financial advisors before making investment decisions. Past spinoff performance does not guarantee future results.